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A matrix metalloproteinase activation probe for
painting human tumours†
Bethany Mills, a Dominic Norberg,a Kevin Dhaliwal,a Ahsan R Akram,a
Mark Bradley b and Alicia Megia-Fernandez *b
A probe that allows specific ‘painting’ of human tumours is described.
Probe activation was mediated by specific matrix metalloproteinases,
resulting not only in disruption of a FRET pair, but in the generation of
a fragment that ‘‘fluorescently paints’’ human tumours. This probe
demonstrated rapid and effective human tumour labelling with the
potential to allow margin detection during surgical resection.
The concept of tissue-based fluorescent labelling has gained
attention as a method for identification of diseased tissue
margins during intra-operative cancer surgery,1–6 made possi-
ble with key advances in imaging instrumentation.7,8 Pivotal
to this has been the development of fluorescent probes
which provide disease-mediated contrast.9 Approved fluores-
cent contrast agents in this area include compounds such as
5-aminolevulinic acid which is selectively up-taken and meta-
bolized by cancerous tissues to generate protoporphyrin IX.10
Other optical agents in clinical studies11 include labelled
nanobodies,12 peptides, such as chlorotoxin (tozuleristide)13
which is currently in phase II/III studies for pediatric CNS
tumours, and the bis-cyclic peptide GE-137, which targets the
human hepatocyte growth factor receptor (c-MET).14 There
are also a wide variety of protease based probes,15–21 with
cathepsins being a key target where signals are generated
by either covalent modification of the enzyme22 or by FRET
dequenching.23,24 Such probes have been able to detect mar-
gins in nonmelanoma skin cancer.25 Other examples of probes
explored for cancer imaging include those targeting DPP-IV for
esophageal cancer,26,27 folate receptor targeted probes,28 PSMA
for prostate cancer29 or those developed by Tsien,30 whereby
MMP-2 activation liberated a cell penetrating peptide that locally
tagged proximal tissue. Matrix metalloproteinase 13 (MMP-13 or
collagenase 3) is an endopeptidase overexpressed in the micro-
environment around both lung tumours and fibrotic tissue, and
has been shown to play a role in early invasive pulmonary
adenocarcinoma.31 MMP-2 and -9 (gelatinase A and B) are
cancer-associated endopeptidases overexpressed in a variety of
malignant tumors and often associated with aggressiveness and
poor prognosis.32,33 Here we report on the rational design, synth-
esis and evaluation on human cancerous tissue of a novel MMP-
imaging agent (3) which allowed MMP-mediated ‘painting’ of
resected human tumour tissue.
The designed probe (3) contained both a FRET pair between
5-carboxyfluorescein (FAM) and the quencher methyl red
reporting on enzyme activity, as well as the incorporation of
an ‘always-on’ far-red fluorophore (an in-house synthesized
Cy5.5, ex/em 670/693 nm) with a spectral window distinct from
FAM and away from tissue autofluorescence. The Cy5.5-
fragment released enzymatically was responsible for the
‘‘tissue-painting’’ ability of the activated probe, which is attri-
butable to the hydrophobicity of this fragment compared to the
parent compound (Fig. 1a).
The peptide sequence (Pro-Phe-Gly-Nle-Lys-bAla, previously
reported as MMP-2,9,13 substrate34,35) was synthesized by
Fmoc solid-phase peptide synthesis on ChemMatrix resin using
Oxyma/DIC as the coupling combination (Scheme 1). At the
carboxy-terminus of the peptide, three replicates of bis-
ethyleneglycol and D-lysine were added to ensure both solubility
and stability against proteases.34 As part of this strategy we
developed a novel Cy5.5 red dye, that was readily prepared on
large scale in 4 steps, and contained a (5-carboxypyridin-2-yl)
group to allow ready incorporation via an amide bond to
the peptide by solid phase methods (ESI† for details). The
Cy5.5, 5-carboxyfluorescein and methyl red were sequentially
incorporated at the amino terminus of the peptide, on the Lys
side chain (after Dde deprotection) and conjugated to the
Lys(N3) residue via azide/alkyne cycloaddition respectively
(Scheme 1 and ESI†). Probe 3 was purified and characterized
by RP-HPLC and MALDI TOF MS and was fully aqueous soluble
(log P 1.5) (ESI† for details).
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Target and off-target proteases were incubated with 3.
Within 15 min, as anticipated, an increase in green fluorescence
(FAM signal) was measurable from the probe incubated with the
active domains of MMP-2, -9 and -13 (Fig. 1b and Fig. S1, ESI†),
which was blockable in the presence of pan-MMP inhibitor
marimastat.
Probe 3 was stable against the off-target proteases (Fig. 1b),
with cleavage by MMPs specifically at GlymNle, as confirmed by
MALDI TOF MS (Fig. S2, ESI†). Importantly the Cy5.5 residue
did not interfere with fluorescence in the green channel following
MMP activation, with data similar to the control compound 4
that contained FAM & methyl red only (see Fig. S3 and S4, ESI†).
In solution the Cy5.5 fluorescence intensity remained constant
before and after cleavage (Fig. 1b), demonstrating that its
intensity was independent of the FRET pairing. HPLC analysis
confirmed that the Cy5.5-fragment obtained after cleavage was
much more hydrophobic than the other two components, with
its retention factor shifting from k = 4.2 for parent compound 3,
to k = 8.0 for the Cy5.5 fragment (Fig. 1c and e), while MMP-13
treatment of the peptide 3 in biphasic buffer/octanol led to
migration of the cleaved Cy5.5-labelled peptide into the octanol
phase (Fig. 1d and Fig. S5, ESI†) demonstrating the hydro-
phobicity ‘‘switch-on’’ upon cleavage.
3 (5 mM) was applied onto human lung tumour tissue, from
three individual patients: two with squamous cell carcinoma and
one with adenocarcinoma (MMPs presence within these tissues
was confirmed by gelatin zymography,36 Fig. S6, ESI†) and imaged
over 30 min (Fig. 2 and ESI† videos) with a fibre-based imaging
Fig. 1 Cleavage of compound 3 by target MMPs and generation of the tissue painting fragment. (a) Mode of action of 3 showing the quenched and non-
quenched fluorophores and resultant tissue staining with the Cy5.5 fragment released following MMP cleavage; (b) cleavage of 3 (5 mM) measured as
fluorescence increase (compared to enzyme-free control) at 15 min; ex/em 485/528 nm (FAM, green bars) and 680/710 nm (Cy5.5, red bars)
(M: marimastat, MMP inhibitor). Data is the mean of three independent replicates performed in duplicate. Error bars represent s.e.m. Statistical analysis
was performed with a one-way ANOVA test compared to an enzyme-free control. *P = 0.0147; ****P o 0.0001; (c) RP-HPLC analysis revealed the
decreased polarity of the Cy5.5-fragment after cleavage compared to the parent peak; (d) visual change in the octanol–water distribution before and
after enzymatic cleavage of 3 showing the generation of the hydrophobic Cy5.5 fragment; (e) structure of 3 showing the fragments generated following
cleavage at the Gly–Nle site by MMPs.
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system,37 at each time point 300 frames were collected over 10 s.
Marimastat (50 mM) was pre-incubated with a separate slice of the
same tissue sample to serve as a control. An increase in FAM
fluorescence (green) was observed over time, which was reduced
in the presence of marimastat. Importantly, whilst the green
fluorescence increased by some B2-fold above tissue autofluor-
escence during the imaging procedure, the Cy5.5 (red) fluores-
cence on the tissue increased by more than 20-fold, differing
significantly from the results seen in vitro, and attributable to the
hydrophobic nature of the cleaved Cy5.5 fragment. Thus, during
enzymatic cleavage, the released Cy5.5 component immediately
‘sticks’ to the tissue in the proximity of the MMP, thus acting as a
‘tumour paint’. By contrast, healthy tissue was interrogated by the
same procedure and activation of probe 3 happened only after
spiking the tissue with MMP-2 or MMP-13 (Fig. S7, ESI†).
The tumour painting ability was further demonstrated by
inspection of a freshly excised lung tissue sample (Fig. 3a),
which contained tumour (adenocarcinoma), macroscopically
normal tissue and a transitional zone in-between within the
single slice. Compound 3 (50 mM) was added to the slice of lung
tissue and imaged after 40 min with a wide-field fluorescence
microscope. This procedure enabled the full tissue to be
examined and fluorescence to be collected at a higher resolu-
tion and from a larger field of view compared to the fibre based
imaging. A clear increase in brightness was demonstrated in
the Cy5.5 fluorescence channel (red) within the adenocarci-
noma region (4.1 fold increase), compared to the adjacent
normal tissue, with a moderate level of fluorescence (2.1 fold
increase) detectable in the transition zone, thus demonstrating
that 3 can be utilized to ‘paint’ tumour margins on freshly
resected tissue. A tissue slice from the same sample was imaged
without the addition of 3 (Fig. 3b). Autofluorescence in the
Cy5.5 channel was akin to that seen within the macroscopically
normal zone of the tissue treated with compound 3, demon-
strating that the adenocarcinoma did not strongly autofluores-
cence within this spectral region, and that the cleaved Cy5.5
fragment enabled tumour margin delineation, with the loca-
lized activated probe adhering onto the tissue, circumventing
diffusion and loss of the signal.
In conclusion, this highly water soluble MMP imaging probe
allows ‘tumour painting’ and provides a quick, simple and
robust method of identifying areas of high MMP activity, with
utility both in vitro, in situ (real-time fibre based imaging) and
ex vivo (microscopic imaging) scenarios. The method has the
potential to guide intraoperative surgery via fluorescent ‘painting’
of tumour margins. Its highly-specific activation (inhibited by
marimastat) leads to novel and highly desirable tissue staining
characteristics and adherence to cancerous human tumour
tissue. Our approach offers advantages over other protease-
activatable probes which may diffuse away from the target
site.17 Other benefits include the speed of probe activation,38
demonstrated with the fibre-based imaging, and the ability to
topically apply the imaging agent.
Scheme 1 Probe synthesis: compound 1 was prepared by SPPS on
chemmatrix resin as detailed in ESI,† after cleavage from the resin it was
reacted with methylred-alkyne (2) by CuAAC click chemistry: (i) 2, CuSO4/
ascorbate, tris(3-hydroxypropyltriazolylmethyl)amine, aminoguanidine,
H2O, 30 1C, 5 h. FAM = 5-carboxyfluorescein, MR = methyl red (see ESI†
for details and characterization).
Fig. 2 Specific activation of 3 by cancerous human lung tumour tissue.
Compound 3 (5 mM) was added to ex vivo human lung cancer tissue
( marimastat, M). The tissue was interrogated using an optical
fibre-based imaging device with 300 frames collected per time-point
(0–30 min) post addition of 3. (a) Individual frame from the 10 s video
(per time-point/condition) is shown. Merge is an overlay of the two
fluorescent channels, which are shown individually within the inserts.
(b) Fold-change in average fluorescence (FAM: green and Cy5.5: red)
after incubation with the compound was compared to base-line
fluorescence from the two channels. At each time point, the mean
intensity of the 300 video frames is shown. Data is from three independent
patient tumour samples with each symbol representing an individual
patient ( marimastat, M). Scale bar is 50 mm.
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Fig. 3 Macroscopic imaging of 3 delineating tumour margins. (a) Bright
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tissue from the same patient sample without the addition of compound 3
was used as a measure of tissue autofluorescence within this spectral
window. Scale bar is 1 mm.
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